Autosomal Recessive Spinocerebellar Ataxia Type 9 (SCAR9)

Autosomal recessive spinocerebellar ataxia type 9 (SCAR9) is a rare inherited brain disorder that mainly affects the cerebellum, the part of the brain that organizes balance and smooth, coordinated movement. “Autosomal recessive” means a child must get one faulty copy of the same gene from each parent to become affected. In SCAR9, the faulty gene is COQ8A (also known as ADCK3). This gene helps the body make coenzyme Q10 (CoQ10)—a vital molecule that lets our cell “batteries” (mitochondria) turn food into usable energy. When COQ8A does not work, CoQ10 levels in certain tissues—especially nervous system and muscle—can be too low. Low CoQ10 makes nerve cells (notably cerebellar Purkinje cells) work poorly and gradually degenerate, causing ataxia and other symptoms. Because the basic problem is CoQ10 production, SCAR9 belongs to the family of primary CoQ10 deficiency disorders, and it is one of the few inherited ataxias that may be partly treatable with CoQ10 in some patients (responses vary). ScienceDirect+4NCBI+4PMC+4

SCAR9 is a rare, inherited brain condition that mainly damages the cerebellum, the part of the brain that controls balance and coordination. It happens when both copies of a gene called COQ8A (also known as ADCK3) carry a disease-causing change. This gene helps the body make coenzyme Q10 (CoQ10), a key molecule that lets mitochondria (the cell’s “power plants”) turn food into energy. When COQ8A is faulty, CoQ10 levels can be low and brain cells—especially Purkinje cells in the cerebellum—do not get enough energy, leading to unsteady walking (ataxia), tremor, eye movement problems, and sometimes seizures or learning issues. Some people improve with high-dose CoQ10 supplements because they replace the missing building block. OUP Academic+3NCBI+3PMC+3

Other names

SCAR9 is known by several overlapping names in medical articles. These include: COQ8A-ataxia, ADCK3-related ataxia, autosomal recessive cerebellar ataxia type 2 (ARCA2), and Primary CoQ10 deficiency-4 (CoQ10D4). These terms all point to the same core disorder: biallelic (two-copy) pathogenic variants in COQ8A causing cerebellar ataxia with evidence of CoQ10 pathway deficiency. NCBI+2MDPI+2

Types

Doctors do not split SCAR9 into rigid “types” the way some diseases are staged, but patients tend to fall into recognizable clinical patterns. Thinking in patterns helps families and clinicians anticipate problems and plan tests:

1. Childhood-onset, movement-predominant ataxia. Many children first show clumsiness, frequent falls, or delayed motor milestones between toddler years and early school age. MRI often shows cerebellar atrophy (shrinkage). Speech can become slurred (dysarthria). The course varies—some children worsen slowly; others plateau for years. NCBI+1

2. Juvenile/adult-onset ataxia with exertional intolerance. Some people develop symptoms in their teens or adulthood, often with fatigability, exercise intolerance, muscle aches, or tremor. They may have milder cerebellar findings but clear coordination problems on examination. Wiley Online Library+1

3. Multisystem (broader) phenotype. A subset has epilepsy, myoclonus, dystonia, migraine-like or “stroke-like” episodes, developmental regression, or learning difficulties. Problems outside the cerebellum reflect widespread mitochondrial energy stress. Wiley Online Library+1

4. Infant/early-childhood severe presentations. Rarely, babies or very young children present with low muscle tone (hypotonia), feeding difficulties, or early developmental delays plus progressive ataxia—again with cerebellar atrophy on MRI. MDPI+1

(These patterns overlap; one person can shift between them over time.) Wiley Online Library

Causes

Strictly speaking, the underlying cause of SCAR9 is pathogenic variants (mutations) in both copies of the COQ8A/ADCK3 gene. Everything below lists either the root genetic factors or common contributors/triggers that can reveal, aggravate, or mimic disease activity in people who already have COQ8A variants:

1. Biallelic COQ8A pathogenic variants (missense, nonsense, frameshift, splice)—the essential cause of SCAR9. ScienceDirect+1

2. Compound heterozygosity (two different harmful COQ8A variants—one from each parent). Wiley Online Library

3. Founder variants in certain populations (same disease-causing change recurring in a community). Wiley Online Library

4. Variant effects on CoQ10 biosynthesis enzymes, reducing CoQ10 in muscle/brain. MedlinePlus

5. Purkinje cell vulnerability—these cerebellar neurons are energy-hungry and degenerate when CoQ10 is low. ScienceDirect

6. Mitochondrial respiratory chain dysfunction (impaired oxidative phosphorylation). PMC

7. Oxidative stress due to poor electron transport and low antioxidant role of CoQ10. MDPI

8. Energy crisis during illness (fevers, infections) can temporarily worsen coordination. MDPI

9. Exertional stress—heavy exercise may unmask fatigue/ataxia in borderline cases. Wiley Online Library

10. Nutritional deficits/low intake (while diet cannot fix the genetic defect, poor nutrition may aggravate fatigue). MDPI

11. Intercurrent metabolic stress (dehydration, electrolyte shifts, e.g., phosphate depletion reported in a case) may worsen symptoms. ResearchGate

12. Sleep deprivation—can worsen gait and tremor in many ataxias, including SCAR9. NCBI

13. Certain medications that depress the cerebellum (e.g., excess sedatives) may aggravate ataxia. (General ataxia guidance.) NCBI

14. Coexisting mitochondrial disorders (rare but reported overlaps) can compound symptoms. MDPI

15. Pubertal/teen growth spurts—energy demand rises and can highlight exercise intolerance. Wiley Online Library

16. Head trauma—can transiently worsen coordination in vulnerable brains. (General ataxia principles.) NCBI

17. Inadequate CoQ10 treatment exposure—brief or low-dose trials may show little benefit, leaving symptoms unchecked. PubMed

18. Genotype-phenotype differences—some variants cause milder or more severe disease. Wiley Online Library

19. Delayed diagnosis—missed early management (therapy, seizure control) permits preventable complications. NCBI

20. Diagnostic confusion with other ataxias—late recognition delays targeted counseling and trials of CoQ10. NCBI

Common symptoms

1. Unsteady walking (gait ataxia). People sway, take wide-based steps, and fall more often because the cerebellum cannot finely tune posture and leg movements. NCBI+1

2. Poor hand coordination. Tasks like writing, buttoning, or using utensils become slow and shaky. Wiley Online Library

3. Slurred speech (dysarthria). Speech sounds “scanning” or broken because mouth and throat muscles are poorly coordinated. NCBI

4. Tremor or action tremor. Hands shake when reaching or holding objects. Wiley Online Library

5. Eye movement problems. Nystagmus (jerky eye movements) or trouble tracking targets can cause dizziness or blurry vision. NCBI

6. Myoclonus or dystonia. Some have sudden jerks or abnormal postures due to network instability beyond the cerebellum. Wiley Online Library

7. Seizures. A significant minority has epilepsy, from brief staring spells to convulsions, requiring EEG and treatment. Wiley Online Library

8. “Stroke-like” or migraine-like episodes. Temporary weakness, confusion, or headache may occur in some patients. Wiley Online Library

9. Fatigue and exercise intolerance. Because cells make energy less efficiently, activity drains more quickly. PMC

10. Developmental delays or regression in children. Skills may come late or sometimes regress during stress or illness. MDPI

11. Falls and injuries. Poor balance increases fall risk and fear of walking. NCBI

12. Fine motor clumsiness. Difficulty with drawing, typing, or playing instruments due to cerebellar dysmetria. NCBI

13. Cognitive or learning difficulties (some cases). Attention, processing speed, or planning may be affected. Wiley Online Library

14. Mood symptoms. Anxiety or low mood can appear as a reaction to disability and possible cerebellar-network effects. NCBI

15. Speech and swallowing fatigue. Long talking or eating can feel tiring or effortful in advanced cases. NCBI

Diagnostic tests

A) Physical examination (bedside observation)

1. Gait assessment. Doctor watches you walk, turn, and stand with feet together; wide stance and swaying suggest ataxia. This is the most basic, high-yield exam step. NCBI

2. Romberg test. Standing with feet together and eyes closed; increased swaying points to balance pathway problems. NCBI

3. Tandem (heel-to-toe) walking. A very sensitive screen for cerebellar dysfunction; difficulty staying on a straight line is typical. NCBI

4. Speech and eye-movement exam. Listening for slurred speech and watching for nystagmus or saccade abnormalities. NCBI

5. Posture and truncal control. Inability to sit or stand steadily without support hints at midline cerebellar involvement. NCBI

B) Manual/bedside coordination tests

6. Finger-to-nose and finger-to-finger. Overshooting the target (dysmetria) and intention tremor are classic cerebellar signs. NCBI

7. Heel-to-shin. Scraping the heel down the opposite shin checks leg coordination; a wobbly or zig-zag movement is typical. NCBI

8. Rapid alternating movements (RAM). Rapidly turning the hands or tapping the foot uncovers dysdiadochokinesia (trouble alternating). NCBI

9. Rebound test. Checking how limbs respond when resistance is suddenly removed; poor check is a cerebellar sign. NCBI

10. Sit-to-stand and Timed 25-Foot Walk. Simple timed tasks quantify severity and track changes over months/years (used in studies and clinics). PubMed

C) Laboratory and pathological tests

11. Genetic testing for COQ8A. The definitive test. Most panels for hereditary ataxia include COQ8A/ADCK3. Exome/genome sequencing can also identify variants. Family testing confirms recessive inheritance. NCBI+1

12. Tissue CoQ10 measurement. Muscle biopsy or fibroblast CoQ10 levels can show deficiency; blood levels are less reliable for brain/muscle status. NCBI

13. Mitochondrial respiratory chain assays (research/selected cases). May show reduced enzyme activities tied to CoQ10 shortage. PMC

14. Metabolic screens. Lactate, creatine kinase, acylcarnitines, and amino acids help rule out other metabolic conditions and can be normal or mildly abnormal in SCAR9. NCBI

15. Basic labs during decompensation. Electrolytes (including phosphate) and glucose to identify reversible triggers that worsen symptoms. ResearchGate

D) Electrodiagnostic tests

16. EEG (electroencephalogram). Recommended if there are spells suggestive of seizures; EEG helps guide anti-seizure therapy. Wiley Online Library

17. EMG/NCS (electromyography/nerve conduction studies). Considered if weakness, cramps, or sensory symptoms suggest peripheral nerve or muscle involvement. NCBI

18. Evoked potentials (selected). Visual or somatosensory evoked potentials can document slowed pathways when exam is unclear. NCBI

E) Imaging tests

19. Brain MRI. The key imaging test. Many patients show cerebellar atrophy, sometimes pronounced, supporting the diagnosis in the right clinical setting. Wiley Online Library

20. MR spectroscopy (selected centers). May show lactate or metabolic changes that support mitochondrial dysfunction, though findings vary. NCBI

Non-pharmacological treatments (therapies & others)

Note: these approaches manage symptoms, maintain function, and reduce complications. They can be tailored by a rehab team (neurology, physio, OT, speech therapy, nutrition).

1. Task-specific physical therapy (PT)
   Goal-directed balance and coordination exercises (eg, gait training, dual-task walking, trunk control drills) improve mobility and reduce falls. Structured programs (about 45-minute sessions, 4–5×/week for several weeks) show gains in ataxia scales and walking independence. Mechanism: repeated practice strengthens neural networks and compensatory strategies. PMC+1

2. Balance & postural control training
   Exercises using stance changes, weight shifts, and unstable surfaces improve postural reflexes. Mechanism: cerebellar adaptation and sensory reweighting. PMC

3. Coordination training (upper-limb & trunk)
   Reaching, object manipulation, and dual-motor tasks enhance accuracy and reduce dysmetria. Mechanism: error-based motor learning in spared cerebellar circuits. Frontiers

4. Gait aids (cane, walker) & orthoses
   Assistive devices increase safety and reduce fall risk during community ambulation; orthoses can stabilize ankles and knees. Mechanism: external support lowers demand on impaired cerebellar control. BioMed Central

5. Occupational therapy (OT)
   Home and work adaptations, energy-conservation, and fine-motor strategies maintain independence in daily tasks. Mechanism: compensatory techniques + environmental optimization. Frontiers

6. Speech and language therapy (SLT)
   For slurred speech and swallowing issues: breath support, pacing strategies, and swallow techniques reduce aspiration risk and improve intelligibility. Mechanism: targeted motor pattern retraining. ACPIN

7. Swallow safety plan & nutrition optimization
   Texture modification, posture techniques, and dietician support prevent weight loss and pneumonia. Mechanism: reduces airway compromise and meets energy needs in mitochondrial disease. BioMed Central

8. Respiratory therapy
   Breathing exercises and cough-assist devices if bulbar or respiratory weakness occurs. Mechanism: preserves ventilation and airway clearance. PMC

9. Home exercise program
   Between supervised blocks, daily home routines maintain gains and slow decline. Mechanism: repetition and plasticity maintenance. PMC

10. Fall-prevention & home hazard reduction
    Lighting, remove loose rugs, install grab bars; teach safe transfers. Mechanism: lowers external triggers for falls. BioMed Central

11. Vision & oculomotor rehab
    Saccade and gaze-holding drills lessen oscillopsia/nystagmus impact. Mechanism: compensatory eye-movement strategies. BioMed Central

12. Cognitive support & educational accommodations
    Attention/processing-speed strategies and school/work plans support participation. Mechanism: environmental and task adjustments. BioMed Central

13. Mental health care (CBT, counseling)
    Reduces anxiety/depression associated with progressive disability; improves adherence and quality of life. Mechanism: coping skills and cognitive reframing. BioMed Central

14. Energy management & fatigue pacing
    Structured rest, activity scheduling, and heat avoidance help mitochondrial-related fatigue. Mechanism: matching energy demand to mitochondrial supply. BioMed Central

15. Community exercise (safe, progressive)
    Walking programs and balance classes complement PT when supervised therapy ends. Mechanism: sustained conditioning and balance challenge. PMC

16. Nutritional counseling in mitochondrial disease
    Adequate calories, hydration, and micronutrients support cellular energy; address weight loss from dysphagia. Mechanism: supports mitochondrial metabolism. umdf.org

17. Genetic counseling
    Explains inheritance (autosomal recessive), carrier risks, and options for family planning. Mechanism: informed decisions and early testing. NCBI

18. Vaccination & infection prevention
    Avoids deconditioning and hospitalization that worsen function. Mechanism: reduces secondary stress on impaired systems. BioMed Central

19. Assistive technology (speech apps, adaptive utensils)
    Compensates for dysarthria and fine-motor issues during daily life. Mechanism: offloading impaired motor control. ACPIN

20. Caregiver education & support groups
    Education (eg, National Ataxia Foundation) helps with resources, safety, and advocacy. Mechanism: empowerment and adherence. National Ataxia Foundation

---

Drug treatments

Important: There are no FDA-approved drugs specifically for SCAR9/COQ8A-ataxia. Medicines below are commonly used off-label to treat symptoms such as spasticity, tremor, dystonia, seizures, mood, sleep, or walking. Doses must be individualized by a clinician; label information is cited from FDA drug labels for safety/side-effects and approved uses in other conditions. BioMed Central

1. Baclofen (oral or intrathecal) – antispasticity (GABA-B agonist). Typical oral titration; intrathecal pump for severe spasticity. Side effects: drowsiness, weakness; pump therapy has specific screening and pump risks. Class: muscle relaxant. Timing: regular dosing; intrathecal continuous. Purpose/Mechanism: reduces muscle tone by spinal inhibition. Source: FDA labels (Lioresal Intrathecal; Lyvispah). FDA Access Data+1

2. Tizanidine – antispasticity (α2-agonist). Titrate slowly to reduce hypotension/sedation; watch withdrawal hypertension. Class: central α2 agonist. Purpose/Mechanism: decreases excitatory spinal signaling. Source: FDA label (Zanaflex). FDA Access Data

3. Clonazepam – for myoclonus/tremor/anxiety (benzodiazepine). Start low, monitor dependence and sedation; boxed warnings on concomitant opioids. Class: benzodiazepine. Purpose/Mechanism: enhances GABA-A inhibition to dampen abnormal movements. Source: FDA label (Klonopin). FDA Access Data

4. Propranolol (Inderal LA) – for action tremor or anxiety (beta-blocker). Titrate; monitor blood pressure/heart rate. Class: non-selective β-blocker. Purpose/Mechanism: reduces peripheral tremor drive and adrenergic symptoms. Source: FDA label (Inderal LA). FDA Access Data

5. Gabapentin – for neuropathic pain/myoclonus adjunct and sleep benefit. Titrate to effect; watch dizziness/somnolence. Class: anticonvulsant/neuropathic pain agent. Mechanism: modulates calcium channels. Source: FDA label (Neurontin). FDA Access Data

6. Levetiracetam – for seizures if present. Generally well-tolerated; monitor mood irritability. Class: antiepileptic. Mechanism: SV2A binding reduces synaptic release. Source: FDA label (Keppra). FDA Access Data

7. Topiramate – for seizures or migraine that worsen ataxia burden; monitor cognition/paresthesias. Class: antiepileptic. Mechanism: multiple (GABA, AMPA/kainate, carbonic anhydrase). Source: FDA label (Topamax). FDA Access Data

8. OnabotulinumtoxinA (targeted injections) – for focal dystonia/spasticity that interferes with care (eg, calf/adductors). Class: neuromuscular blocker (local). Mechanism: blocks acetylcholine release at neuromuscular junction. Source: FDA label (BOTOX). FDA Access Data

9. Dalfampridine (Ampyra) – off-label trial for gait speed; approved for MS walking. Seizure risk higher with renal impairment; do not exceed 10 mg twice daily. Class: potassium-channel blocker. Mechanism: improves conduction in demyelinated axons; may aid motor output. Source: FDA label (Ampyra). FDA Access Data

10. Amantadine / amantadine ER – off-label for fatigue or dyskinesia-like movements; monitor confusion/insomnia/livedo reticularis. Class: dopaminergic/antiviral. Mechanism: dopaminergic and NMDA effects. Source: FDA reviews/labels (Symmetrel; Gocovri). FDA Access Data+1

11. Trihexyphenidyl – off-label for dystonia/tremor in selected patients; anticholinergic side effects (dry mouth, confusion). Class: anticholinergic. Mechanism: reduces cholinergic tone. Source: FDA Artane/ANDA materials. FDA Access Data+1

12. Carbidopa/Levodopa – off-label trial if parkinsonian features coexist; monitor nausea, dyskinesia. Class: dopaminergic replacement. Mechanism: dopamine precursor with peripheral decarboxylase inhibitor. Source: FDA label (Sinemet; DHIVY; CR). FDA Access Data+2FDA Access Data+2

13. SSRIs (eg, sertraline, fluoxetine) – for depression/anxiety common in chronic neurologic disease; monitor suicidality warnings. Class: antidepressants. Mechanism: serotonin reuptake inhibition. Source: FDA labels (Zoloft; Prozac). FDA Access Data+1

14. Propranolol (short-acting) – as needed for performance tremor/anxiety spikes that worsen coordination tasks; same cautions as LA. Class/Mechanism: β-blocker reducing adrenergic drive. Source: FDA propranolol labeling. FDA Access Data

15. Clonazepam (night dosing) – for nocturnal myoclonus or severe sleep-fragmenting tremor; use lowest dose, short term if possible. Class/Mechanism: benzodiazepine enhancing GABA-A. Source: FDA label. FDA Access Data

16. Gabapentin (sleep/neuropathic adjunct) – bedtime dosing can improve pain and sleep quality; watch daytime sedation. Class/Mechanism: calcium channel α2δ modulation. Source: FDA label. FDA Access Data

17. Topiramate (migraine prevention) – migraine can worsen balance; topiramate may reduce attacks but can impair cognition—balance risks/benefits. Class/Mechanism: broad antiepileptic. Source: FDA label. FDA Access Data

18. OnabotulinumtoxinA (sialorrhea/blepharospasm) – targeted relief when drooling or eyelid spasm interferes with care/vision. Mechanism: local cholinergic blockade. Source: FDA label. FDA Access Data

19. Levetiracetam (status/ICU use) – useful for seizure clusters; monitor mood. Mechanism: SV2A binding. Source: FDA IV label. FDA Access Data

20. Avoid/Use with extreme caution: Valproic acid – in primary mitochondrial disease (especially POLG-related) it can trigger liver failure; many experts advise avoiding until POLG disease is ruled out. If no alternative, specialist monitoring is essential. Purpose of mention: safety. Mechanism risk: mitochondrial hepatotoxicity. Source: expert consensus and safety literature. PMC+2umdf.org+2

---

Dietary molecular supplements

Discuss with your clinician; quality and dosing vary. The best evidence in SCAR9 is for CoQ10.

1. Coenzyme Q10 (ubiquinone/ubiquinol) – 5–50 mg/kg/day (often 300–1200 mg/day in divided doses). Function: replaces the missing mitochondrial electron-carrier, improving energy production. Mechanism: restores electron transport chain flow and antioxidant capacity; several COQ8A cases show improved ataxia and even seizure control. American Academy of Neurology+3NCBI+3PMC+3

2. Riboflavin (vitamin B2) – cofactor for mitochondrial flavoproteins; sometimes used with CoQ10 to support oxidative phosphorylation. Mechanism: enhances complex I/II activity. PMC

3. Thiamine (vitamin B1) – supports pyruvate dehydrogenase; trialed in mitochondrial energy failure and ataxic syndromes. Mechanism: improves carbohydrate entry into Krebs cycle. PMC

4. Alpha-lipoic acid – mitochondrial antioxidant that recycles glutathione; theoretical support for reducing oxidative stress. Mechanism: redox cofactor and ROS scavenger. PMC

5. Vitamin E – lipid-phase antioxidant that protects neuronal membranes; low risk with monitoring. Mechanism: limits oxidative damage to Purkinje cells. PMC

6. Acetyl-L-carnitine – shuttles fatty acids into mitochondria; may improve fatigue. Mechanism: supports mitochondrial β-oxidation. PMC

7. Creatine – cellular energy buffer (phosphocreatine system); sometimes used to aid muscle energetics. Mechanism: stabilizes ATP availability. PMC

8. N-acetylcysteine (NAC) – glutathione precursor; counters oxidative stress. Mechanism: replenishes antioxidant defenses. PMC

9. Omega-3 fatty acids – neuroprotective and anti-inflammatory; supportive for general brain health. Mechanism: membrane stabilization and anti-inflammatory signaling. PMC

10. Multivitamin with minerals – covers general micronutrient needs in those with poor intake from dysphagia. Mechanism: prevents secondary deficiencies that worsen fatigue. umdf.org

---

Immunity-booster / regenerative / stem-cell” drugs

Plain truth: There are no FDA-approved regenerative or stem-cell drugs for SCAR9 or hereditary ataxias. Experimental cell or gene therapies should only be taken in IRB-approved clinical trials. Below are supportive, FDA-approved medicines sometimes used in mitochondrial/neurologic care—not “regenerative” cures—and why they’re used; anything marketed as stem-cell therapy outside trials should be avoided. BioMed Central

1. OnabotulinumtoxinA – reduces focal spasticity/dystonia to ease care and prevent contractures; not disease-modifying. Dose: individualized injection cycles (about every 12 weeks). Function/Mechanism: local cholinergic blockade at neuromuscular junction. FDA Access Data

2. Baclofen (intrathecal) – for severe spasticity unresponsive to oral therapy; implanted pump delivers continuous dosing. Function/Mechanism: GABA-B agonism in spinal cord reduces tone. FDA Access Data

3. Dalfampridine – may modestly improve walking speed (approved for MS); occasionally tried off-label to support ambulation practice in ataxia rehab. Function/Mechanism: potassium-channel blockade enhances conduction. FDA Access Data

4. Amantadine ER – sometimes used to reduce dyskinesia-like movements or fatigue; not regenerative. Mechanism: dopaminergic/NMDA effects. FDA Access Data

5. Carbidopa/Levodopa – symptomatic relief if parkinsonian features coexist; not disease-modifying. Mechanism: dopamine replacement. FDA Access Data

6. Levetiracetam (IV or PO) – seizure control to protect brain from status epilepticus injury; supportive only. Mechanism: SV2A binding reduces hyperexcitability. FDA Access Data

---

Surgeries/procedures

1. Intrathecal baclofen pump implantation – for severe spasticity when oral drugs fail or cause intolerable side effects; improves care, pain, and positioning. FDA Access Data

2. Botulinum toxin chemodenervation – targeted injections for focal dystonia/sialorrhea/blepharospasm to improve comfort and function. FDA Access Data

3. Feeding tube (PEG) placement – if severe swallowing problems cause weight loss or aspiration; ensures safe nutrition/hydration. BioMed Central

4. Orthopedic procedures (eg, tendon lengthening, scoliosis surgery) – if contractures or spinal deformities limit function or cause pain. ACPIN

5. Laryngology/airway procedures – selected cases with severe aspiration may need airway protection strategies planned by a multidisciplinary team. BioMed Central

---

Prevention tips

1. Early CoQ10 supplementation after diagnosis, under medical guidance, because COQ8A-ataxia is one of the few ataxias with potential treatment response. NCBI

2. Structured fall-prevention (PT, home safety, gait aids). PMC

3. Vaccinations & prompt infection care to avoid deconditioning. BioMed Central

4. Regular swallow checks to prevent aspiration and weight loss. ACPIN

5. Bone health basics (nutrition, activity) to reduce fracture risk from falls. BioMed Central

6. Mental health screening (depression/anxiety) and early therapy. BioMed Central

7. Genetic counseling for family planning and carrier testing. NCBI

8. Avoid valproate unless essential and POLG disease excluded, due to mitochondrial hepatotoxicity risk. PMC

9. Plan regular rehab “booster” blocks after supervised programs to maintain gains. PMC

10. Link with ataxia foundations for education and resources. National Ataxia Foundation

---

When to see a doctor (red flags)

See a neurologist promptly if you notice worsening unsteadiness, frequent falls, choking or weight loss from swallowing issues, new seizures, rapid vision change/oscillopsia, severe mood changes, or sudden decline after infection. Early review allows adjustments to rehab, nutrition, and CoQ10 therapy; seizures or aspiration need urgent care. BioMed Central+1

Foods to eat / to avoid

Eat more:

1. balanced meals with protein at each meal;
2. colorful fruits/vegetables;
3. whole grains if tolerated;
4. healthy fats (olive oil, nuts, omega-3 fish);
5. dairy or fortified alternatives for calcium/vitamin D;
6. adequate fluids soft/moist textures if swallowing is hard;
7. small, frequent meals to fight fatigue;
8. CoQ10-rich foods (meats, oily fish) as adjunct to supplements;
9. high-calorie oral nutritional supplements when losing weight. umdf.org

Limit/avoid:

1. alcohol (worsens balance);
2. sedating drinks (excessive nighttime teas/antihistamine mixes);
3. ultra-processed high-sugar foods that spike-crash energy;
4. dehydration;
5. very hard/dry foods if dysphagia (nuts/chips) unless adapted;
6. thin liquids if advised by SLT—use thickeners;
7. fad “mitochondrial cleanses” without evidence;
8. mega-doses of single vitamins without supervision;
9. unregulated “stem-cell” products;
10. medications known to pose mitochondrial risks without specialist review (notably valproate in suspected POLG disease). ACPIN+2umdf.org+2

---

FAQs

1) Is SCAR9 the same as COQ8A-ataxia?
Yes. SCAR9, COQ8A-ataxia, ADCK3-ataxia, and ARCA2 are different names for the same genetic disease caused by COQ8A mutations. NCBI

2) Why does it cause ataxia?
Low CoQ10 impairs mitochondrial energy in Purkinje cells, leading to poor timing of muscle activity and balance errors. ScienceDirect

3) Can CoQ10 help?
Many patients with COQ8A-ataxia improve on high-dose CoQ10; dosing often ranges 5–50 mg/kg/day, using well-absorbed formulations. NCBI

4) When should I start CoQ10?
As soon as COQ8A deficiency is diagnosed, because earlier treatment may yield better neurologic responses. MDPI

5) Are there FDA-approved drugs for SCAR9?
No. Drug therapy targets symptoms (spasticity, tremor, seizures, mood) and is off-label for ataxia itself. BioMed Central

6) What about stem-cell therapy?
No approved stem-cell or regenerative drugs for hereditary ataxias; consider only IRB-approved trials. BioMed Central

7) Can rehab really help?
Yes. Structured PT/OT/SLT improves balance, mobility, daily skills, and safety even in progressive ataxias. PMC

8) Are seizures part of SCAR9?
They can be. If present, standard antiseizure drugs like levetiracetam or topiramate are used, and some cases improved after CoQ10. FDA Access Data+2FDA Access Data+2

9) Is valproate safe?
Often avoided in primary mitochondrial disease—especially with suspected POLG variants—because of liver failure risk. PMC

10) How is it inherited?
Autosomal recessive: each parent is typically a healthy carrier; each child has a 25% chance to be affected. NCBI

11) What does MRI show?
Usually cerebellar atrophy; sometimes other mitochondrial signs depending on the case. PMC

12) Do diet changes cure it?
No, but good nutrition and dysphagia-safe textures support energy and prevent complications; CoQ10 is the key targeted supplement. umdf.org+1

13) How fast does it progress?
Often slowly progressive from childhood/adolescence, with variability between families and even within families. PMC

14) Are there research advances?
Yes—better genetic testing, CoQ10 response predictors, and rehab protocols; pathophysiology work continues. ScienceDirect

15) Where can families get support?
National Ataxia Foundation and rare-disease organizations offer education and community links. National Ataxia Foundation

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 05, 2025.

PDF Documents For This Disease Condition References